In the past week, SPRO stock has gone up by 19.48%, with a monthly gain of 11.66% and a quarterly plunge of -9.92%. The volatility ratio for the week is 8.49%, and the volatility levels for the last 30 days are 4.84% for Spero Therapeutics Inc The simple moving average for the past 20 days is 15.03% for SPRO’s stock, with a -22.20% simple moving average for the past 200 days.
Is It Worth Investing in Spero Therapeutics Inc (NASDAQ: SPRO) Right Now?
Spero Therapeutics Inc (NASDAQ: SPRO) has a price-to-earnings ratio that is above its average at 11.32x. The stock has a 36-month beta value of 0.60. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for SPRO is 36.63M, and at present, short sellers hold a 1.16% of that float. On March 26, 2025, the average trading volume of SPRO was 192.37K shares.
SPRO) stock’s latest price update
The stock price of Spero Therapeutics Inc (NASDAQ: SPRO) has jumped by 9.97 compared to previous close of 0.82. Despite this, the company has seen a gain of 19.48% in its stock price over the last five trading days. globenewswire.com reported 2025-03-18 that CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025.
Analysts’ Opinion of SPRO
Many brokerage firms have already submitted their reports for SPRO stocks, with Evercore ISI repeating the rating for SPRO by listing it as a “In-line.” The predicted price for SPRO in the upcoming period, according to Evercore ISI is $5 based on the research report published on December 20, 2024 of the previous year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see SPRO reach a price target of $8, previously predicting the price at $2. The rating they have provided for SPRO stocks is “Outperform” according to the report published on September 23rd, 2022.
SPRO Trading at 9.31% from the 50-Day Moving Average
After a stumble in the market that brought SPRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.33% of loss for the given period.
Volatility was left at 4.84%, however, over the last 30 days, the volatility rate increased by 8.49%, as shares surge +12.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.27% lower at present.
During the last 5 trading sessions, SPRO rose by +19.48%, which changed the moving average for the period of 200-days by -38.00% in comparison to the 20-day moving average, which settled at $0.7815. In addition, Spero Therapeutics Inc saw -12.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRO starting from Keutzer Timothy, who sale 56,537 shares at the price of $0.78 back on Feb 05 ’25. After this action, Keutzer Timothy now owns 741,439 shares of Spero Therapeutics Inc, valued at $44,099 using the latest closing price.
Rajavelu Esther, the CFO & CBO of Spero Therapeutics Inc, sale 20,689 shares at $0.78 during a trade that took place back on Feb 05 ’25, which means that Rajavelu Esther is holding 724,720 shares at $16,137 based on the most recent closing price.
Stock Fundamentals for SPRO
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 1.05 for the gross margin
The net margin for Spero Therapeutics Inc stands at 0.04. The total capital return value is set at -0.09. Equity return is now at value 5.90, with 2.90 for asset returns.
Based on Spero Therapeutics Inc (SPRO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.79. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is 25.77 million with net debt to EBITDA at 73.71. When we switch over and look at the enterprise to sales, we see a ratio of -0.24. The receivables turnover for the company is 1.79for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.68.
Conclusion
To sum up, Spero Therapeutics Inc (SPRO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
